Japan & Korea Biotech Showcase at Bayer Co.Lab Cambridge

We are pleased to invite you to an exclusive, invitation-only biotech showcase at Bayer Co.Lab Cambridge on September 24, 2026. The event will bring together a curated group of seven innovative biotechnology companies from Japan and South Korea, alongside venture investors, founders, and industry leaders from the Greater Boston ecosystem. The showcase offers a unique opportunity to meet companies actively pursuing strategic partnerships, financing opportunities, and expansion into the U.S. market. Several of the participating companies are engaging with the Boston biotech ecosystem for the first time, providing attendees with early visibility into emerging innovation before it becomes broadly known within U.S. investor networks. The participating companies range from emerging venture-backed innovators to clinical-stage biotechnology companies developing novel therapeutics and platform technologies across gene therapy, exosome therapeutics, microbiome science, AI-enabled drug discovery, and precision medicine. This event is part of Bayer Co.Lab Connect, an initiative designed to strengthen connections between global innovation hubs and foster partnerships among founders, investors, and industry leaders. Featured Panel Discussion Internationalization: Increasing Appeal on a Global Stage Uli Stilz, Senior Partner, Flagship Pioneering Matt Stanton, Founder & CEO, Typewriter More to come! Agenda & Schedule: 15:00 - 15:30, Doors Open for Networking 15:30 - 15:35, Opening Remarks 15:35 - 16:15, Panel Discussion: Internationalization: Increasing Appeal on a Global Stage 16:15 - 16:45, Company Presentations 16:45 - 16:50, Closing Remarks 16:50 - 18:00, Founder & Investor Networking Reception and Co.Lab Tour Participating Companies This showcase will feature seven innovative biotech companies from Japan and South Korea advancing differentiated platforms across exosome therapeutics, AAV gene therapy, tumor-selective replicating gene therapy, novel small molecules and ADCs, mRNA-based in vivo antibody production, precision medicine, and translational therapeutic technologies. ILIAS Biologics – Clinical-stage exosome therapeutics platform for inflammatory and fibrotic diseases. Elisigen – Clinical-stage AAV gene therapy company developing transformative, one-time treatments for chronic retinal diseases and neuropathic pain. artiCure – IND-enabling oncology company advancing tumor-selective replicating gene therapies for solid tumors. Genome & Company – First-in-class drug discovery company advancing novel therapeutic targets in oncology and fibrosis through differentiated small molecule and ADC programs. Crafton Biotechnology – mRNA therapeutics company pioneering in vivo production of antibodies for autoimmune and other indications. Kanjin Therapeutics – Precision medicine company developing next-generation therapeutic solutions for unmet medical needs. Curigin – Innovative biotech company advancing novel therapeutic approaches and translational technologies. Attendance Attendance is limited to a select group of invited venture investors, founders, and industry leaders from the Greater Boston life sciences ecosystem. We encourage early registration, as capacity is limited.